Clinical experience with isavuconazole in healthy volunteers and patients with invasive aspergillosis in China, and the results from an exposure–response analysis-Reference-Cited by-同舟云学术

Clinical experience with isavuconazole in healthy volunteers and patients with invasive aspergillosis in China, and the results from an exposure–response analysis

Published:2021-01-31 Issue:4 Volume:64 Page:445-456
ISSN:0933-7407
Container-title:Mycoses
language:en
Short-container-title:Mycoses

Author:

Zhang Jing¹,Zhang Yingyuan¹,Wu Depei²,Cao Guoying¹,Hamed Kamal³^ORCID,Desai Amit⁴,Aram Jalal A.⁵^ORCID,Guo Xuan⁶,Fayyad Rana⁵,Cornely Oliver A.⁷⁸⁹^ORCID

Affiliation:

1. Institute of Antibiotics, Huashan Hospital Fudan University Shanghai China

2. Department of Hematology the First Affiliated Hospital of Soochow University Suzhou China

3. Basilea Pharmaceutica International Ltd. Basel Switzerland

4. Astellas Pharma Inc Northbrook IL USA

5. Pfizer Inc New York City NY USA

6. Pfizer Inc Beijing China

7. University of Cologne, Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Excellence Center for Medical Mycology (ECMM) Cologne Germany

8. Cologne Excellence Cluster on Cellular Stress Responses in Aging‐Associated Diseases (CECAD) Cologne Germany

9. Clinical Trials Centre Cologne (ZKS Köln) Cologne Germany

Funder

Pfizer

Publisher

Wiley

Subject

Infectious Diseases,Dermatology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/myc.13233

Reference30 articles.

1. Epidemiology and Antifungal Susceptibility Profile of Aspergillus Species: Comparison between Environmental and Clinical Isolates from Patients with Hematologic Malignancies